Hangzhou Xian Shi Biotechnology Co., Ltd.

Established in 2020 and based in Hangzhou, China, Hangzhou Xian Shi Biotechnology Co. , Ltd. is a high-tech company focusing on biomaterials and regenerative medicine industry, and develops next-generation tissue regeneration materials with Zhejiang University, Shanghai Jiao Tong University and many other key laboratories at provincial and ministerial level. The company's core team consists of scientists, doctors and engineers from the fields of biomaterials and regenerative medicine, and has won awards such as the Innovation Award in the 2021-SATOL (China) Life Science and Technology Innovation and Entrepreneurship Competition.

In June 2023, the company closed a round of series A funding. The company has its own four major technology platforms including decellularization technology platform, hydrogel microsphere platform, electrostatic spinning nanofiber platform and bionic mineralization platform, the platforms are used to developed a variety of tissue regeneration material products, such as endometrial repair materials, breast reconstruction filling materials, etc. In 2023, the company's first endometrial repair product, a highly adherent decellularized matrix microfiber material, completed registration for clinical trials.